Video

Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma (mRCC).

For the phase III study presented at the 2019 Genitourinary Cancers Symposium, investigators randomized patients to receive either pembrolizumab (Keytruda) plus axitinib (Inlyta) or sunitinib (Sutent). Progression-free survival was clearly superior with the immunotherapy/TKI combination compared with the standard TKI alone, Agarwal says. Objective response rates were 59% with the combination versus 36% with sunitinib. Further, the checkpoint inhibitor and TKI combination significantly increased overall survival in these patients.

Based on this data, pembrolizumab plus axitinib seems to be a promising new option for patients with mRCC, Agarwal notes, although the complete response rates with the combination were lower than those seen the FDA-approved combination of nivolumab (Opdivo) and ipilimumab (Yervoy)—5% versus 11% in favor of the PD-1/CTLA-4 inhibitor combination. Agarwal says this is the only qualm he has with pembrolizumab plus axitinib.

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS